Castle Biosciences (CSTL) Q2 2026 Earnings Call Transcript

Castle Biosciences reported Q2 2026 total revenue of $103.5M, up 20.1% YoY, with core growth of 40% excluding DecisionDx-SCC and IDgenetix. The company raised full-year 2026 revenue guidance to $365M–$375M (from $345M–$355M) as TissueCypher volume grew 63.4% YoY to 14,988 reports, while DecisionDx-Melanoma held at 10,280 reports (+3% YoY). Despite gross margin pressure (adjusted GM 76.3% vs 79.5% YoY) and higher operating expenses ($106.6M vs $90.4M), Adjusted EBITDA improved to $12.4M and management expects positive adjusted EBITDA for 2026. Reimbursement/regulatory progress is notable, including a proposed AdvanceAD-Tx Medicare crosswalk rate of $3,675 per test based on a 21–0 panel vote, supporting the outlook.

Analysis

This reads as a quality-growth inflection, but the market should separate durable demand from reimbursement optics. The real mechanism is that CSTL is turning a single-product commercial motion into a multi-product account model, which raises customer lifetime value but temporarily taxes melanoma productivity and margins. That tradeoff is usually rewarded only after investors see repeat ordering and payer conversion, so the next 1-2 quarters matter more than the top-line beat itself.

The biggest second-order winner is CSTL’s own installed base: once one clinician adopts, additional products can piggyback on the same sales call, lowering future CAC per test. The loser is gross margin near term—lab supplies, headcount, and SG&A are rising ahead of full reimbursement monetization—so the stock can stall if investors conclude growth is being bought rather than harvested. Specialty diagnostics peers without a reimbursement path may get multiple compression if CSTL proves it can scale with positive EBITDA and a large cash cushion.

Catalysts are clustered: CMS final pricing for AdvanceAD-Tx in late September, Medicare LCD reconsideration for SCC in 2H26, and any 3Q evidence that melanoma volumes re-accelerate after the commercial model change. The contrarian risk is that consensus is over-reading the raised revenue guide while underweighting maturity risk in TissueCypher and the fact that the new product ramp is still small in absolute dollars. Thesis is falsified if 3Q melanoma growth stays stuck at low single digits, AdvanceAD-Tx fails to convert into reimbursed volume, or adjusted gross margin slips materially below the low-70s guide range.

Key Decisions for Investors

• Long CSTL on pullbacks into the next 2-4 weeks; target 15-20% upside into the 2H26 reimbursement catalysts, but only if 3Q commentary confirms repeat ordering in AdvanceAD-Tx and no deterioration in melanoma volume.
• For a lower-beta expression, buy CSTL Jan-2027 call spreads rather than stock: the setup is catalyst-rich but reimbursement timing is uneven, so defined-risk upside is cleaner than chasing spot after a strong print.
• Pair trade: long CSTL / short a broader diagnostics proxy or weaker reimbursement-franchised lab name if one is available in your book, to isolate execution-plus-reimbursement alpha from sector multiple noise.
• Set a watch item on the late-September CMS rate notice: if the final AdvanceAD-Tx rate comes in meaningfully below the proposed level, cut the thesis by 30-50% because the launch curve will likely slip into 2027.
• If CSTL rallies hard before 3Q results, trim into strength unless melanoma sequential growth re-accelerates; the stock is likely to need proof that the commercial model change is additive, not dilutive.